Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma

Inclusion Criteria: * Relapsed or refractory follicular lymphoma grade I-II * Tumor verified to be CD20 positive * CT scan showing demarcated lesions Exclusion Criteria: * Previous treatment with rituximab resulting in less than partial response * Previous radioimmunotherapy * Previous stem cell transplantation * Received the following treatments within 4 weeks prior to entering this study: 1. Anti-cancer therapy 2. Glucocorticosteroids unless less than 10 mg prednisolone/day 3. Radiotherapy * Received Mitomycin C or Nitrosoureas within 6 weeks prior to entering this trial * HIV positivity * Hepatitis B or hepatitis C * Uncontrolled or chronic bacterial, fungal or viral infection * Other cancer diseases, except certain skin cancers, cervix cancer and breast cancer * Certain serious medical conditions, including kidney or liver disease, some psychiatric illnesses, and stomach, lung, heart, hormonal, nerve or blood diseases * WHO performance status of 3 or 4 * If you are participating in another trial with a different new drug 4 weeks before you enter this trial * Current participation in any other clinical study * Pregnant or breast-feeding women * Women of childbearing age who are unable or unwilling to use an IUD or hormonal birth control during the whole trial